Metagenomi Therapeutics (MGX) Operating Expenses (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Operating Expenses of $25.8 million for Q1 2026, down 19.13% year-over-year from $31.9 million in Q1 2025, and down 8.64% quarter-over-quarter from $28.3 million in Q4 2025.
Metagenomi Therapeutics (MGX) Operating Expenses (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Operating Expenses for 4 consecutive years, with $25.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 19.13% year-over-year to $25.8 million; the TTM figure through Mar 2026 stood at $115.1 million (down 13.42% YoY), while the FY2025 annual figure was $121.2 million, down 14.15% from the prior year.
- Operating Expenses slipped to $25.8 million in Q1 2026 per MGX's latest filing, from $28.3 million in the prior quarter.
- Across five years, Operating Expenses topped out at $40.2 million in Q1 2024 and bottomed at $25.8 million in Q1 2026.
- Historically, Operating Expenses has averaged $31.7 million across 4 years, with a median of $31.5 million in 2025.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 51.12% — and 2025, when it decreased 20.51%.
- Metagenomi Therapeutics' Operating Expenses stood at $32.6 million in 2023, then dropped by 7.23% to $30.2 million in 2024, then fell by 6.48% to $28.3 million in 2025, then dropped by 8.64% to $25.8 million in 2026.
- Business Quant data shows MGX's Operating Expenses at $25.8 million in Q1 2026, $28.3 million in Q4 2025, and $31.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | 28.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.52 Mn |
| Mar 31, 2026 | 25.84 Mn |
| Dec 31, 2025 | 28.28 Mn |
| Sep 30, 2025 | 31.50 Mn |
| Jun 30, 2025 | 29.50 Mn |
| Mar 31, 2025 | 31.95 Mn |
| Dec 31, 2024 | 30.24 Mn |
| Sep 30, 2024 | 33.90 Mn |
| Jun 30, 2024 | 36.87 Mn |
| Mar 31, 2024 | 40.19 Mn |
| Dec 31, 2023 | 32.60 Mn |
| Sep 30, 2023 | 34.76 Mn |
| Jun 30, 2023 | 29.30 Mn |
| Mar 31, 2023 | 26.60 Mn |